Insuman Comb 25 Injection is a premixed insulin formulation containing 75% insulin isophane (NPH insulin) and 25% soluble human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This combination provides both intermediate-acting and short-acting insulin components, allowing for improved glycemic control by addressing both basal and prandial insulin requirements. Insulin isophane acts to maintain basal insulin levels, while the soluble human insulin component facilitates rapid onset of action to manage postprandial glucose excursions. Insuman Comb 25 is indicated for adult patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not provide adequate glycemic control. The injection is administered subcutaneously, typically before meals, with dosing individualized based on patient needs, blood glucose monitoring, and clinical response. Careful attention must be given to avoid hypoglycemia, the most common adverse effect, by adjusting doses in response to changes in diet, physical activity, or concomitant medications. Patients should be educated on proper injection technique, storage requirements, and recognition of hypoglycemia symptoms. Insuman Comb 25 should be used under medical supervision as part of a comprehensive diabetes management plan.